1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
Murphy, K.E.; Karaconji, T.; Hardman, C.D.; Halliday, G.M. Excessive dopamine neuron loss in progressive supranuclear palsy.
Mov. Disord. 2008, 23, 607–610. [CrossRef]
Mastaglia, F.L.; Grainger, K.; Kee, F.; Sadka, M.; Lefroy, R. Progressive supranuclear palsy (the Steele–Richardson–Olszewski
syndrome) clinical and electrophysiological observations in eleven cases. Proc. Aust. Assoc. Neurol. 1973, 10, 35–44.
Alster, P.; Madetko, N.; Koziorowski, D.; Friedman, A. Progressive supranuclear palsy—Parkinsonism predominant (PSP-P)—A
clinical challenge at the boundaries of PSP and Parkinson’s disease (PD). Front. Neurol. 2020, 11, 180. [CrossRef]
DelveInsight. Progressive supranuclear palsy (PSP)—Epidemiology forecast. Available online: https://www.researchandmarkets.
com/reports/5025131/progressive-supranuclear-palsy-psp (accessed on 3 October 2021).
National Institute of Neurological Disorders and Stroke Progressive Supranuclear Palsy Fact Sheet. Available online: https://
www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Fact-Sheets/Progressive-Supranuclear-Palsy-Fact-Sheet (accessed
on 10 October 2021).
Bakar, Z.H.A.; Kato, T.; Yanagisawa, D.; Bellier, J.-P.; Mukaisho, K.-i.; Tooyama, I. Immunohistochemical study of mitochondrial
ferritin in the midbrain of patients with progressive supranuclear palsy. Acta Histochem. Cytochem. 2021, 54, 97–104. [CrossRef]
Nogami, A.; Yamazaki, M.; Saito, Y.; Hatsuta, H.; Sakiyama, Y.; Takao, M.; Kimura, K.; Murayama, S. Early stage of progressive
supranuclear palsy: A neuropathological study of 324 consecutive autopsy cases. J. Nippon Med. Sch. 2015, 82, 266–273. [CrossRef]
Albers, D.S.; Beal, M.F. Mitochondrial dysfunction in progressive supranuclear palsy. Neurochem. Int. 2002, 40, 559–564. [CrossRef]
Albers, D.S.; Swerdlow, R.H.; Manfredi, G.; Gajewski, C.; Yang, L.; Parker, W.D., Jr.; Beal, M.F. Further evidence for mitochondrial
dysfunction in progressive supranuclear palsy. Exp. Neurol. 2001, 168, 196–198. [CrossRef]
Gao, G.; Chang, Y.Z. Mitochondrial ferritin in the regulation of brain iron homeostasis and neurodegenerative diseases. Front.
Pharmacol. 2014, 5, 19. [CrossRef]
Levi, S.; Corsi, B.; Bosisio, M.; Invernizzi, R.; Volz, A.; Sanford, D.; Arosio, P.; Drysdale, J. A human mitochondrial ferritin encoded
by an intronless gene. J. Biol. Chem. 2001, 276, 24437–24440. [CrossRef]
Corsi, B.; Cozzi, A.; Arosio, P.; Drysdale, J.; Santambrogio, P.; Campanella, A.; Biasiotto, G.; Albertini, A.; Levi, S. Human
mitochondrial ferritin expressed in HeLa cells incorporates iron and affects cellular iron metabolism. J. Biol. Chem. 2002, 277,
22430–22437. [CrossRef]
Nie, G.; Sheftel, A.D.; Kim, S.F.; Ponka, P. Overexpression of mitochondrial ferritin causes cytosolic iron depletion and changes
cellular iron homeostasis. Blood 2005, 105, 2161–2167. [CrossRef]
Yang, H.; Yang, M.; Guan, H.; Liu, Z.; Zhao, S.; Takeuchi, S.; Yanagisawa, D.; Tooyama, I. Mitochondrial ferritin in neurodegenerative diseases. Neurosci. Res. 2013, 77, 1–7. [CrossRef]
Yang, H.; Guan, H.; Yang, M.; Liu, Z.; Takeuchi, S.; Yanagisawa, D.; Vincent, S.R.; Zhao, S.; Tooyama, I. Upregulation of
mitochondrial ferritin by proinflammatory cytokines: Implications for a role in Alzheimer’s disease. J. Alzheimers Dis. 2015, 45,
797–811. [CrossRef]
Gao, G.; Zhang, N.; Wang, Y.Q.; Wu, Q.; Yu, P.; Shi, Z.H.; Duan, X.L.; Zhao, B.L.; Wu, W.S.; Chang, Y.Z. Mitochondrial ferritin
protects hydrogen peroxide-induced neuronal cell damage. Aging Dis. 2017, 8, 458–470. [CrossRef]
Kandimalla, R.; Manczak, M.; Yin, X.; Wang, R.; Reddy, P.H. Hippocampal phosphorylated tau induced cognitive decline,
dendritic spine loss and mitochondrial abnormalities in a mouse model of Alzheimer’s disease. Hum. Mol. Genet. 2018, 27, 30–40.
[CrossRef]
Reddy, P.H.; Oliver, D.M. Amyloid beta and phosphorylated tau-induced defective autophagy and mitophagy in Alzheimer’s
disease. Cells 2019, 8, 488. [CrossRef]
Manczak, M.; Reddy, P.H. Abnormal interaction between the mitochondrial fission protein Drp1 and hyperphosphorylated tau
in Alzheimer’s disease neurons: Implications for mitochondrial dysfunction and neuronal damage. Hum. Mol. Genet. 2012, 21,
2538–2547. [CrossRef]
Wang, X.; Yang, H.; Yanagisawa, D.; Bellier, J.P.; Morino, K.; Zhao, S.; Liu, P.; Vigers, P.; Tooyama, I. Mitochondrial ferritin affects
mitochondria by stabilizing HIF-1α in retinal pigment epithelium: Implications for the pathophysiology of age-related macular
degeneration. Neurobiol. Aging 2016, 47, 168–179. [CrossRef]
Towers, C.G.; Wodetzki, D.K.; Thorburn, J.; Smith, K.R.; Caino, M.C.; Thorburn, A. Mitochondrial-derived vesicles compensate
for loss of LC3-mediated mitophagy. Dev. Cell 2021, 56, 2029–2042.e5. [CrossRef]
Swerdlow, N.S.; Wilkins, H.M. Mitophagy and the brain. Int. J. Mol. Sci. 2020, 21, 9661. [CrossRef]
Piras, A.; Collin, L.; Grüninger, F.; Graff, C.; Rönnbäck, A. Autophagic and lysosomal defects in human tauopathies: Analysis of
post-mortem brain from patients with familial Alzheimer disease, corticobasal degeneration and progressive supranuclear palsy.
Acta Neuropathol. Commun. 2016, 4, 22. [CrossRef]
Li, L.; Wang, X.; Fei, X.; Xia, L.; Qin, Z.; Liang, Z. Parkinson’s disease involves autophagy and abnormal distribution of cathepsin
L. Neurosci. Lett. 2011, 489, 62–67. [CrossRef]
Liu, B.; Sun, J.; Zhang, J.; Mao, W.; Ma, Y.; Li, S.; Cheng, X.; Lv, C. Autophagy-related protein expression in the substantia nigra
and Eldepryl intervention in rat models of Parkinson’s disease. Brain Res. 2015, 1625, 180–188. [CrossRef]
Int. J. Mol. Sci. 2022, 23, 537
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.
42.
43.
44.
45.
14 of 14
Boman, A. Lysosomal Network Proteins as Biomarkers and Therapeutic Targets in Neurodegenerative Disease. Ph.D. Thesis,
Linköping University, Linköping, Sweden, 15 November 2015.
Krüger, U.; Wang, Y.; Kumar, S.; Mandelkow, E.M. Autophagic degradation of tau in primary neurons and its enhancement by
trehalose. Neurobiol. Aging 2012, 33, 2291–2305. [CrossRef]
Wang, Y.; Mandelkow, E. Degradation of Tau protein by autophagy and proteasomal pathways. Biochem. Soc. Trans. 2012, 40,
644–652. [CrossRef]
Wang, Y.; Martinez-Vicente, M.; Krüger, U.; Kaushik, S.; Wong, E.; Mandelkow, E.M.; Cuervo, A.M.; Mandelkow, E. Tau
fragmentation, aggregation and clearance: The dual role of lysosomal processing. Hum. Mol. Genet. 2009, 18, 4153–4170.
[CrossRef]
Lee, M.J.; Lee, J.H.; Rubinsztein, D.C. Tau degradation: The ubiquitin–proteasome system versus the autophagy-lysosome system.
Prog. Neurobiol. 2013, 105, 49–59. [CrossRef]
Hansen, T.E.; Johansen, T. Following autophagy step by step. BMC Biol. 2011, 9, 39. [CrossRef]
Yoo, S.M.; Jung, Y.K. A molecular approach to mitophagy and mitochondrial dynamics. Mol. Cells 2018, 41, 18–26.
Sarkar, C.; Zhao, Z.; Aungst, S.; Sabirzhanov, B.; Faden, A.I.; Lipinski, M.M. Impaired autophagy flux is associated with neuronal
cell death after traumatic brain injury. Autophagy 2014, 10, 2208–2222. [CrossRef]
Cui, D.; Sun, D.; Wang, X.; Yi, L.; Kulikowicz, E.; Reyes, M.; Zhu, J.; Yang, Z.J.; Jiang, W.; Koehler, R.C. Impaired autophagosome
clearance contributes to neuronal death in a piglet model of neonatal hypoxic-ischemic encephalopathy. Cell Death Dis. 2017,
8, e2919. [CrossRef]
Long, Z.; Chen, J.; Zhao, Y.; Zhou, W.; Yao, Q.; Wang, Y.; He, G. Dynamic changes of autophagic flux induced by Abeta in the
brain of postmortem Alzheimer’s disease patients, animal models and cell models. Aging 2020, 12, 10912–10930. [CrossRef]
Wang, L.; Yang, H.; Zhao, S.; Sato, H.; Konishi, Y.; Beach, T.G.; Abdelalim, E.M.; Bisem, N.J.; Tooyama, I. Expression and
localization of mitochondrial ferritin mRNA in Alzheimer’s disease cerebral cortex. PLoS ONE 2011, 6, e22325. [CrossRef]
Alster, P.; Madetko, N.; Koziorowski, D.; Friedman, A. Microglial activation and inflammation as a factor in the pathogenesis of
progressive supranuclear palsy (PSP). Front. Neurosci. 2020, 14, 893. [CrossRef]
Filomeni, G.; De Zio, D.; Cecconi, F. Oxidative stress and autophagy: The clash between damage and metabolic needs. Cell Death
Differ. 2015, 22, 377–388. [CrossRef]
Trist, B.G.; Hare, D.J.; Double, K.L. Oxidative stress in the aging substantia nigra and the etiology of Parkinson’s disease. Aging
Cell 2019, 18, e13031. [CrossRef]
Wang, X.; Ma, H.; Sun, J.; Zheng, T.; Zhao, P.; Li, H.; Yang, M. Mitochondrial ferritin deficiency promotes osteoblastic ferroptosis
via mitophagy in Type 2 diabetic osteoporosis. Biol. Trace Elem. Res. 2021, 200, 298–307. [CrossRef]
Kageyama, Y.; Saito, A.; Pletnikova, O.; Rudow, G.L.; Irie, Y.; An, Y.; Murakami, K.; Irie, K.; Resnick, S.M.; Fowler, D.R. Amyloid β
toxic conformer has dynamic localization in the human inferior parietal cortex in absence of amyloid plaques. Sci. Rep. 2018,
8, 1–17.
Abdelalim, E.M.; Tooyama, I. Mapping of NPR-B immunoreactivity in the brainstem of Macaca fascicularis. Brain Struct. Funct.
2011, 216, 387–402. [CrossRef]
Yang, M.; Yang, H.; Guan, H.; Kato, T.; Mukaisho, K.; Sugihara, H.; Ogasawara, K.; Terada, T.; Tooyama, I. Characterization of
a novel monoclonal antibody against human mitochondrial ferritin and its immunohistochemical application in human and
monkey substantia Nigra. Acta Histochem. Cytochem. 2017, 50, 49–55. [CrossRef]
Stauffer, W.; Sheng, H.; Lim, H.N. EzColocalization: An ImageJ plugin for visualizing and measuring colocalization in cells and
organisms. Sci. Rep. 2018, 8, 1–13. [CrossRef]
Meshlab. Available online: https://www.meshlab.net/ (accessed on 20 September 2021).
...
論文の公開元へ
